Semmelweis University, Second Department of Obstetrics and Gynecology, Budapest, Hungary.
Eur J Obstet Gynecol Reprod Biol. 2012 Mar;161(1):12-7. doi: 10.1016/j.ejogrb.2011.12.013. Epub 2012 Jan 11.
To assess 11-β-hydroxysteroid dehydrogenase 2 (11β-HSD2) gene expression patterns in human placental samples from intrauterine growth restriction (IUGR) pregnancies using normal pregnancy as control.
We compared 11-β-HSD2 gene expression in placental samples from all IUGR pregnancies treated in our clinic between January 1, 2010 and January 1, 2011 vs. 140 normal pregnancy samples from the same study period. Clinical characteristics were also assessed and compared between the IUGR and normal pregnancy groups.
Mean gestational weight gain in the IUGR group was significantly lower than in the control group. Similarly, change in body mass index (BMI) was lower. Impending intrauterine fetal asphyxia was significantly more common in the IUGR group. The 11β-HSD2 gene was underexpressed compared to controls, but this underexpression was only observed after the 33rd gestational week. Within the IUGR group, in cases of impending intrauterine fetal asphyxia the 11β-HSD2 gene was underexpressed compared to both impending asphyxia in non-IUGR cases, or IUGR without impending asphyxia.
Low gestational weight gain appears to predict IUGR. The 11β-HSD2 gene in IUGR is underexpressed and may result in an impaired placental barrier, decreasing protection against maternal glucocorticoids, which are thought to be prominent in fetal programming. Maternal glucocorticoid exposure resulting from an impaired placental barrier may increase the risk for cardiovascular and metobolic disorders later in adult life. In IUGR, before the 33rd gestational week, the expression of the 11β-HSD2 gene remains physiological. The underexpression of this gene after the 33rd week in impending intrauterine fetal asphyxia in IUGR points to an increased sensitivity to hypoxia when impending asphyxia is present in the late phase of IUGR pregnancies.
评估人类胎盘组织中 11-β-羟类固醇脱氢酶 2(11β-HSD2)基因在宫内生长受限(IUGR)妊娠中的表达模式,以正常妊娠为对照。
我们比较了 2010 年 1 月 1 日至 2011 年 1 月 1 日期间在我们诊所治疗的所有 IUGR 妊娠患者的胎盘样本与同期 140 例正常妊娠样本中的 11β-HSD2 基因表达。还评估并比较了 IUGR 组和正常妊娠组的临床特征。
IUGR 组的平均孕体重增长明显低于对照组。同样,体重指数(BMI)的变化也较低。IUGR 组中宫内胎儿窘迫的发生率明显较高。11β-HSD2 基因的表达低于对照组,但仅在 33 孕周后观察到这种低表达。在 IUGR 组中,在即将发生宫内胎儿窘迫的情况下,与非 IUGR 病例中即将发生的胎儿窘迫或无胎儿窘迫的 IUGR 相比,11β-HSD2 基因表达较低。
低孕体重增长似乎可预测 IUGR。IUGR 中的 11β-HSD2 基因表达下调,可能导致胎盘屏障受损,降低对母体糖皮质激素的保护作用,而母体糖皮质激素被认为在胎儿编程中起重要作用。受损的胎盘屏障导致的母体糖皮质激素暴露可能增加成年后心血管和代谢紊乱的风险。在 IUGR 中,在 33 孕周之前,11β-HSD2 基因的表达保持生理状态。在 33 孕周后,在 IUGR 中即将发生宫内胎儿窘迫时,该基因的低表达表明在 IUGR 妊娠晚期即将发生胎儿窘迫时,对缺氧的敏感性增加。